IMHO a big catalyst will be results of preclinical trials into other neurodegenerative indications.
At the moment we have all our eggs in the ALS basket which carries a fair amount of risk. If it looks like we can bring a second indication into play then that both increases our addressable market and also spreads the risk.
I'd imagine that strong preclinical results in a second indication could easily result in a doubling of the current share price.
- Forums
- ASX - By Stock
- PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
IMHO a big catalyst will be results of preclinical trials into...
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.5¢ |
Change
0.015(8.82%) |
Mkt cap ! $82.65M |
Open | High | Low | Value | Volume |
17.5¢ | 18.5¢ | 17.5¢ | $110.2K | 620.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 172857 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 275901 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 183662 | 0.175 |
4 | 105394 | 0.170 |
2 | 287747 | 0.165 |
5 | 354112 | 0.160 |
9 | 210434 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 202500 | 5 |
0.190 | 196600 | 3 |
0.195 | 260704 | 8 |
0.200 | 1145496 | 13 |
0.205 | 122000 | 1 |
Last trade - 10.11am 26/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online